A federal appeals court in New Orleans just upended the way most abortions are carried out in the United States.

On May 1, the U.S. Court of Appeals for the Fifth Circuit issued a nationwide stay of the FDA’s 2023 rules that allowed mifepristone, the most widely used abortion drug in America, to be prescribed through telehealth appointments and mailed directly to patients. The order is effective immediately and restores the pre-2021 requirement that patients pick up the drug in person at a clinic or qualified provider’s office.

The ruling came from a three-judge panel acting on a challenge brought by Louisiana officials, who argued the FDA’s loosened rules amounted to an end-run around state abortion laws. In granting the stay under 5 U.S.C. § 705, the court found that Louisiana had demonstrated real sovereign and financial injury, and that the FDA itself admitted it was still collecting safety data and could not say when its review would be finished.

That last detail is significant. A federal agency that cannot tell a court when it will complete its own safety review is not in a strong position to defend the regulatory changes it made while that review was still open.

The Fifth Circuit Court of Appeals laid out its reasoning plainly:

ADVERTISEMENT

The Fifth Circuit granted a stay of the FDA’s 2023 REMS regime for mifepristone, finding that the agency had replaced strict in-person dispensing requirements with a system that allowed online prescribing and mail-order delivery. In granting that stay under 5 U.S.C. § 705, the judges said they were persuaded by Louisiana’s sovereign-interest and irreparable-harm arguments and by records that showed the earlier order permitting remote use had returned to a court review path that remained unstable. The panel did not limit its view to abstract policy disagreement: it described the FDA as having formally admitted it was still collecting data and could not provide a firm date for completing a full safety review. The order therefore reinstates the pre-2021 in-person model for all mifepristone prescriptions and is effective while the case proceeds. The court also referenced Louisiana’s claim that the 2023 rules had made enforcement gaps in its own abortion restrictions practical, not theoretical, under the circumstances presented.

The practical impact hits fast and hits everywhere. That change affects patients and clinics in all 50 states, because the order targets the federal regulatory framework, not any one state law.

As the Associated Press reported:

The report says the Fifth Circuit ruling restricts prescription abortions through mailed mifepristone in practice, pushing access back to in-person clinical pickup and dispensing. The AP coverage says the framework this order affects was national in scope and reaches patients in all states, not just those with strict abortion statutes. It also notes that the ruling is expected to significantly reshape abortion operations because telehealth prescribing and mail fulfillment had become central in many markets, including areas where providers relied on compliant clinic-based telehealth channels. The story reports that Danco and GenBioPro sought emergency relief from the Supreme Court, and that the case is now on a very fast timeline of filings before any stable operating standard returns. AP adds that women and clinics may face immediate scheduling and travel burdens, especially in medically underserved regions where telehealth options had become the practical path. The wider coverage frames the order as a major reset in abortion logistics and a key prelude to whether the Supreme Court will allow the stays to stay in place.

That last point deserves attention. A majority of abortions in the United States are now medication-based rather than surgical. The telehealth-and-mail pipeline was not a niche option. It had become the dominant delivery system in many parts of the country. This court order pulls the plug on that system until the legal fight is resolved.

Drug manufacturers Danco and GenBioPro have already filed emergency requests asking the Supreme Court to pause the Fifth Circuit’s stay. That means the nine justices could be weighing in on this within days or weeks, not months.

The constitutional stakes are clear. Louisiana’s core argument is about state sovereignty: that when the FDA unilaterally loosened distribution rules for a drug used to end pregnancies, it effectively overrode the ability of individual states to enforce their own laws on the subject. The Fifth Circuit found that argument credible enough to grant an extraordinary remedy.

President Donald Trump has consistently held that life issues should be decided by the states, not dictated by executive-branch regulatory maneuvers. This ruling aligns squarely with that principle. It does not ban mifepristone. It says the FDA cannot bypass its own prior safety requirements and state regulatory authority at the same time, especially while it admits it hasn’t finished studying the consequences.

For the average voter, here is what changes right now: if you or someone you know was obtaining mifepristone through a telehealth visit and mail delivery, that option is off the table until further court action. Prescriptions must be obtained in person from a certified provider.

ADVERTISEMENT

The next move belongs to the Supreme Court, and given the emergency posture of the filings already headed its way, a decision on whether to let this stay stand could come very soon.

 

Join The Conversation. Leave a Comment.